Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Articles
  4. Insights
  5. Ma

M&A

Evaluate

July 05, 2023

Medtech dealmaking grinds almost to a halt

M&A moves are down, venture rounds few and IPOs nonexistent.

July 04, 2023

Biopharma buyouts bounce back

Developers brush off antitrust scrutiny and drug price curbs and succumb to the urge to merge.

Article image
Vantage logo
April 11, 2023

Pfizer's fortunes overshadow first-quarter dealmaking

Aside from Seagen, small takeouts dominate the first quarter.

Article image
Vantage logo
January 11, 2023

Few big bangs in a quiet year for medtech mergers

J&J's $17bn swoop for Abiomed accounted for 42% of medtech M&A spend last year.

Article image
Vantage logo
January 11, 2023

Biopharma’s bolt-on bonanza is set to continue

With interest rates rising and developers focusing on favourite therapy areas, should hopes for mega-deals be reined in?

Article image
Vantage logo
January 10, 2023

Amgen saves biopharma’s buyout year

December’s $28bn takeout of Horizon bumps 2022’s M&A numbers to respectable levels.

Article image
Vantage logo
November 09, 2022

Takeout premiums hold up, but that’s not the whole story

Research-stage buyouts are as expensive as ever, while commercial assets look to be getting dearer, a new analysis finds.

Article image
Vantage logo
October 05, 2022

No big bang for biopharma buyouts

Pfizer's Covid cash keeps the M&A scene alive, but few other developers dug deep in a quiet third quarter.

Article image
Vantage logo
September 05, 2022

Buyouts provide no shortcut to success

M&A is back, but how often do deals pay off?

Article image
Vantage logo
July 20, 2022

The other shoe finally drops for device dealmaking

A combination of Covid and market gloom results in the fewest acquisitions closing for over 20 years.

Article image
Vantage logo
July 05, 2022

Takeout spend ticks up

M&A is back on the menu, but there are still reasons to be cautious.

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...
Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up